Can be Heat Shock Transcription Factor 1 a Potential Target for Hyperthermic Therapy?
スポンサーリンク
概要
- 論文の詳細を見る
Hyperthermia (HT) has been considered a promising approach in cancer therapy. However, the acquisition of thermoresistance in tumor due to several responses of tumor, such as an increase in heat shock proteins (HSPs), makes HT less effective. The induction of HSPs is mainly mediated by the activation of heat shock transcription factor 1 (HSF1). It has been shown that HSF1 is abundantly expressed in human tumor cells of various origins. Moreover, it takes part in the initiation and maintenance of tumor. Silencing of HSF1 could suppress tumor formation and enhance the effectiveness of HT. In this review, the physiological and pathological roles of HSF1 in cancer cells are summarized, and its potential as a therapeutic target for hyperthermic therapy is discussed.
- 日本ハイパーサーミア学会の論文
日本ハイパーサーミア学会 | 論文
- わが国における温熱療法のあゆみと現状:2004年のアンケート調査
- 癌治療における併用療法としての低温度温熱処置の有用性について
- The Biology of Heat-induced DNA Double-Strand Breaks
- 良好な生存率を示した非小細胞肺癌の化学療法とハイパーサーミアの併用療法
- 温熱感受性ならびに温熱効果の修飾について